IQVIA (NYSE:IQV) Price Target Cut to $279.00

IQVIA (NYSE:IQV) had its price target trimmed by JPMorgan Chase & Co. from $288.00 to $279.00 in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

IQV has been the subject of several other reports. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Tuesday, October 22nd. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Truist Financial reduced their price objective on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a report on Monday, October 14th. Morgan Stanley increased their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Finally, UBS Group increased their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $267.27.

IQVIA Stock Performance

IQV stock opened at $214.63 on Wednesday. The firm has a market cap of $39.11 billion, a PE ratio of 29.32, a P/E/G ratio of 2.22 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The business has a 50 day moving average of $237.63 and a 200-day moving average of $230.60. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of IQV. Versant Capital Management Inc increased its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the second quarter worth $27,000. Park Place Capital Corp bought a new stake in IQVIA during the 3rd quarter valued at $28,000. Itau Unibanco Holding S.A. purchased a new stake in IQVIA during the 2nd quarter valued at $29,000. Finally, Riverview Trust Co bought a new stake in IQVIA in the 1st quarter worth $32,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.